Search

Displaying results 7821 - 7830 of 10000 in total
  1. Drug

    Stamulumab

    go.drugbank.com/drugs/DB05915
    Investigational

    MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.

  2. Drug

    CT-011

    go.drugbank.com/drugs/DB05916
    Investigational

    It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities. … CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies.

  3. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.

  4. Drug

    Pegdinetanib

    go.drugbank.com/drugs/DB05931
    Investigational

    CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis … As a result, CT-322 blocks all known ligands for VEGFR-2.

    Categories: Vascular Endothelial Growth Factor Receptor-2, antagonists & inhibitors
  5. Drug

    MK-4721

    go.drugbank.com/drugs/DB05933
    Investigational

    MK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients

  6. Drug

    CTCE-0214

    go.drugbank.com/drugs/DB05934
    Experimental

    CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood

  7. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  8. Drug

    Edonerpic

    go.drugbank.com/drugs/DB05938
    Investigational

    Edonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.

    Categories: Heterocyclic Compounds, 1-Ring
  9. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection.

  10. Drug

    Varlitinib

    go.drugbank.com/drugs/DB05944
    Investigational

    Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. … Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring